索磷布韦联合PR方案治疗慢性丙肝对患者肝损伤标志物、免疫因子及肝纤维化指标的影响

doi:10.3969/j.issn.1671-7171.2022.05.007

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1199 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨索磷布韦联合PR方案治疗慢性丙肝(CHC)对患者肝损伤标志物、免疫因子及肝纤维化指标的影响。【方法】入住两院的CHC患者134例,依据随机数字表法分为观察组与对照组,每组67例。对照组给予PR方案治疗,观察组给予PR方案联合索磷布韦治疗。观察两组治疗前后血清谷草转氨酶(AST)、谷丙转氨酶(ALT)、高尔基体蛋白73(GP73)、铁蛋白(SF)等肝损伤标志物水平;血清CD4⁺、CD8⁺、CD4⁺/CD8⁺等免疫因子水平;血清层粘连蛋白(LN)、透明质酸(HA)、3型前胶原蛋白(PCⅢ)、4型胶原蛋白(C-Ⅳ)等肝纤维化指标的变化及不良反应发生情况。【结果】治疗后,观察组血清AST、ALT、GP73及SF水平均低于对照组(P<0.05);观察组血清CD4⁺、CD4⁺/CD8⁺水平均低于对照组,CD8⁺水平高于对照组(P<0.05);观察组血清LN、HA、PCⅢ、C-Ⅳ水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】索磷布韦联合PR方案治疗CHC可有效清除丙肝病毒,改善免疫因子水平,抑制肝纤维化,降低肝损伤标志物及肝纤维化指标水平,其疗效显著,且安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	卓鑫
	裴媛媛

关键词 ：丙型肝炎,慢性, 抗病毒药/治疗应用, 肝/损伤, 免疫因子类, 肝硬化

Abstract：【Objective】 To investigate the effects of sothibuvir combined with PR regimen on liver injury markers, immune factors and liver fibrosis in patients with chronic hepatitis C (CHC). 【Methods】 A total of 134 patients with CHC admitted to the two hospitals were randomly divided into observation group and control group, with 67 cases in each group. The control group was treated with PR regimen, and the observation group was treated with PR regimen combined sothibuvir. The levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), Golgi protein 73 (GP73), ferritin (SF) and other markers of liver injury were observed before and after treatment; Serum CD4⁺, CD8⁺, CD4⁺/CD8⁺ and other immune factors; Changes of liver fibrosis indexes such as serum laminin (LN), hyaluronic acid (HA), type 3 procollagen (PCⅢ), type 4 collagen (C-Ⅳ) and occurrence of adverse reactions; 【Results】 After treatment, the levels of serum AST, ALT, GP73 and SF in the observation group were lower than those in the control group (P<0.05); The levels of serum CD4⁺, CD4⁺/CD8⁺ in the observation group were lower than those in the control group, and the level of CD8⁺ was higher than that in the control group (P<0.05); The levels of serum LN, HA, PCⅢ and C-Ⅳ in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Sorfosbuvir PR regimen combined with CHC can effectively eliminate Hepatitis C virus, improve the level of immune factors, inhibit liver fibrosis, and reduce the level of liver injury markers and indicators of liver fibrosis. It is effective, safe and reliable.

Key words： Hepatitis C, Chronic Antiviral Agents/TU Liver/SU Immunologic Factors Liver Cirrhosis

收稿日期: 2021-12-26

中图分类号:

R512.63

基金资助:陕西省科技厅项目(2021JM-472)

通讯作者: **E-mail:415288112@qq.com

引用本文:

卓鑫, 裴媛媛. 索磷布韦联合PR方案治疗慢性丙肝对患者肝损伤标志物、免疫因子及肝纤维化指标的影响[J]. 医学临床研究, 2022, 39(5): 664-666.
ZHUO Xin, PEI Yuan-yuan. Effects of Sothibuvir Combined with PR Regimen on Markers of Liver Injury, Immune Factors and Indicators of Liver Fibrosis in Patients with Chronic Hepatitis C. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 664-666.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.05.007 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I5/664